根据2017年欧洲肺癌大会（ELCC）发布的一项II期POPLAR试验的事后分析（post-hoc analysis）结果，即使现行RECIST标准评估为疾病进展，一些晚期肺癌患者仍然能从免疫治疗中获益（96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR）。

评论发言